MDXG Q2 2023 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M+21.5% YoY

Gross Profit

$68M83.3% margin

Operating Income

$11M13.3% margin

Net Income

$1M1.5% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$176M

Total Liabilities

$97M

Stockholders' Equity

$80M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$67M	+21.5%
Gross Profit	$68M	$55M	+22.9%
Operating Income	$11M	-$10M	+212.5%
Net Income	$1M	-$11M	+111.0%

Revenue Segments

Advanced Wound Care

$81M50%

Advanced Wound Care, Tissue And Other

$75M46%

Advanced Wound Care, Umbilical Cord-Derived

$6M4%

Section 351

$19,0000%